<DOC>
	<DOCNO>NCT01773421</DOCNO>
	<brief_summary>This study consist two Parts . Part A ( Food Effect Study ) Part B ( Determination MTD BID Dosing ) .Part A initiated first , Part B initiate PK result Part A evaluate .</brief_summary>
	<brief_title>An Open-label , Dose Escalation , Pharmacodynamic , Pharmacokinetic , Effect Food Phase 1 Study E7820 Determine Maximum Tolerated Dose Following Twice Daily Oral Administration Subjects With Unresectable Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Age 18 year old . 2 . Histological cytological evidence unresectable refractory solid tumor . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 4 . Subjects know brain metastasis eligible follow condition A . Have undergone complete surgical excision 1 month post surgery radiographic evidence brain disease recurrence B . Have undergone stereotactic radio surgery ( gamma knife procedure ) 1 month post procedure radiographic evidence brain disease progression C. Are asymptomatic D. Discontinued corticosteroid treatment least 30 day prior Cycle 1 , Day 1 5 . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN ( case liver metastases less equal 5 x ULN ) In case alkaline phosphatase great 3 x ULN ( absence liver metastasis ) great 5 x ULN ( presence liver metastasis ) AND subject also know bone metastasis , liver specific alkaline phosphatase must separate total use ass liver function instead total alkaline phosphatase . 6 . Adequate renal function evidence serum creatinine less equal 2.0 mg/dL ( 177 micromol/L ) calculate creatinine clearance great equal 40 mL/min per Cockcroft Gault formula 7 . Provide write informed consent . 8 . Are willing able comply aspect protocol . 9 . Adequate bone marrow function evidence absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , hemoglobin great equal 9 g/dL ( 5.5 mmol/L ) platelet count great equal 100 x 109/L . 10 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ betahCG ] test minimum sensitivity 25 IU/L equivalent unit betahCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . 11 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group , without know suspected cause ) sterilize surgically ( i.e. , bilateral tubal ligation , total hysterectomy , bilateral oophorectomy , surgery least 1 month dose ) . 12 . Females childbearing potential must unprotected sexual intercourse within 30 day prior study entry must agree use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] , contraceptive implant , oral contraceptive vasectomized partner confirm azoospermia ) throughout entire study period 30 day study drug discontinuation . If currently abstinent , subject must agree use doublebarrier method describe becomes sexually active study period 30 day study drug discontinuation . Females use hormonal contraceptive must stable dose hormonal contraceptive product least 4 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 13 . Male subject must successful vasectomy ( confirm azoospermia ) female partner must meet criterion ( i.e. , childbearing potential practicing highly effective contraception throughout study period 30 day study drug discontinuation ) . No sperm donation allow study period 30 day study drug discontinuation . 1 . Leptomeningeal metastasis brain metastasis ( except inclusion criterion # 4 ) . 2 . Active hemoptysis ( least 2.5 mL [ 0.5 teaspoon ] bright red blood ) within 3 week prior first dose study drug . 3 . Hypersensitivity sulfonamide derivative . 4 . Subjects radiation great equal 30 % bone marrow . 5 . Subjects require therapeutic anticoagulant therapy warfarin relate vitamin K antagonist . Prophylactic dos heparin low molecular weight heparin thrombin inhibitor may use place warfarin . 6 . Left ventricular ejection fraction le 50 % echocardiography MUGA scanning . 7 . Anticancer therapy complete least 28 day ( 42 day case mitomycin C nitrosoureas ) prior treatment E7820 ( surgery treatment protein kinase inhibitor must complete less one week prior treatment E7820 ) . 8 . Incomplete recovery previous radiotherapy , chemotherapy , surgery residual cutaneous effect stable less Grade 2 gastrointestinal toxicity . 9 . History ischemic cardiac event , myocardial infarction unstable cardiac disease within 3 month study entry . 10 . A clinically significant electrocardiogram ( ECG ) abnormality , include mark baseline prolongation QTc interval great 480 msec . 11 . Evidence clinically significant disease ( e.g. , cardiac , respiratory , gastrointestinal , renal disease ) opinion investigator ( ) could affect subject 's safety study conduct . 12 . Concurrent treatment CYP3A4 inhibitor verapamil , cyclosporin , quinidine , erythromycin , mibefradil , clarithramycin azoles . 13 . Concurrent treatment drug know extensively metabolize CYP2C9 and/or CYP2C19 . 14 . Chronic treatment know inducer CYP3A4 within four week receive treatment E7820 corticosteroid ( Appendix 6 ) . 15 . Subjects positive test result human immunodeficiency virus ( HIV ) , hepatitis A , hepatitis B hepatitis C. 16 . Psychotic disorder ( ) unstable recurrent affective disorder ( ) evident use antipsychotic prior suicide attempt ( ) within approximately last 2 year . 17 . History drug alcohol dependency abuse within approximately last 2 year . 18 . Presence progressive central nervous system ( CNS ) disease , include degenerative CNS disease progressive tumor . 19 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen . 20 . Use illegal recreational drug . 21 . Any medical condition , opinion investigator , would preclude subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>